MIT Advances Its Quest to Identify Life-Threatening Bacteria

SAN CLEMENTE, CA--(Marketwire - December 10, 2007) - Micro Imaging Technology (OTCBB: MMTC) today announced technical advances have occurred in its laser-based MIT 1000 microbial rapid identification system that can identify the life-threatening bacterial strain Methicillin Resistant Staphylococcus aureus (MRSA).

The System can now identify (four) 4 different Staphylococcus aureus (Staph) strain types including the MRSA strain. MIT's ultimate goal is to enable the MIT 1000 system to rapidly (within minutes of culturing) differentiate MRSA from non-resistant 'Staph' bacteria.

As reported in an earlier press release, Staphylococcus aureus or 'Staph,' the most common cause of Staph infections, is a bacterium frequently living on the skin or in the nose of a person and can cause a range of illnesses from minor skin infections, like pimples, boils, and abscesses, to life-threatening diseases, such as pneumonia, meningitis, and toxic shock syndrome. Some strains of Staph bacteria have become resistant to common antibiotics, including methicillin, oxacillin, penicillin and amoxicillin. These bacteria have become known as Methicillin Resistant Staphylococcus aureus or MRSA.

In November 2007, the Centers for Disease Control reported that in 2005 over 278,000 people were diagnosed and hospitalized for MRSA related infections and incidents are increasing at a rate from 6% to over 9% annually throughout the four major regions of the United States.

In addition, resistant strains of E. coli (ESBL E. coli) infections are rapidly increasing. According to an article published in July 2007 from the University of Pittsburgh, "Extended-spectrum B-lactamase (ESBL)-producing organisms have become a common problem for patients in hospitals and other healthcare facilities. Community-onset ESBL infections have recently been described in Spain, the United Kingdom, Israel, and Canada. These organisms may be resistant to most or all antimicrobial agents commonly used to treat urinary tract infections, such as ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin, and ceftriaxone.

"In the United Kingdom, 25 of the first 108 patients with documented community-onset ESBL-producing E. coli infections died. Frequent occurrence of ESBL-producing E. coli in the United States would be an important public health problem and may necessitate changes in empiric antimicrobial therapy."

MIT recently started research in this area and is already able to identify (nine) 9 different strains of E. coli.

John Ricardi, MIT's Vice President, Business Development, stated, "We are very encouraged with the advancements made in the past several months and expect further progress will be achieved in both areas in early 2008. Advancing the MIT 1000 capability to rapidly identify and differentiate antibiotic resistant bacteria from 'treatable' bacteria should provide health care centers with a useful tool to help isolate and control life-threatening bacterial infections."

About Micro Imaging Technology

The Company has developed and patented a technology for rapid microbe detection and identification. The system measures scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. The MIT System is non-biological and does not rely on biological agents, conventional chemical processing, fluorescent tags, gas chromatography or DNA analysis.

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, Shigella and other pathogenic bacteria. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The Test Report, in the Company's opinion, demonstrated the accuracy, speed and efficiency of the MIT system over conventional processes and is available from the Company. The MIT 1000 System was recently featured in the Rapid Microbiology international newsletter. The article can be viewed at www.rapidmicrobiology.com/news/1231n0.ph.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

Contact Information: CONTACT: Michael Brennan Chairman Email: Telephone: (805) 557-0614